ArticleMaterials today. Bio2026
Target FADS1-arachidonic acid-ferroptosis axis: A metabolic bridge linking matrix stiffness to PDAC stemness.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The elevated stiffness of extracellular matrix (ECM), one of the typical physical hallmarks of pancreatic ductal adenocarcinoma (PDAC), which was proved to promote stemness and leads to adverse prognosis. Therefore, to dissect the underlying mechanisms between matrix stiffness and stemness is important. To this end, stiffness tunable hydrogel based on polyacrylamide (PA) was employed to simulate the stiffness of PDAC microenvironment. Our results illustrated that stiff matrix enhanced PDAC (MIA PaCa-2 and PANC-1 cells) stemness by inhibiting ferroptosis. Lipidomic analyses further revealed that matrix stiffness reprogrammed medium and long chain fatty acid metabolism, with particularly prominent arachidonic acid (AA) depletion. Intriguingly, AA supplementation restored ferroptosis sensitivity and reversed stiffness-induced stemness enhancement. Mechanistically, matrix stiffness inhibits AA content by downregulating FADS1 (fatty acid desaturase 1), a key biosynthesis enzyme. Simultaneously, the ferroptosis was suppressed accompanied by the AA reduction, which was validated via decreased lipid peroxidation and preserved mitochondrial morphology. Besides, FADS1 knockdown recapitulated the stiff matrix effects, causing ferroptosis inhibition and stemness enhancement, which could be rescued by AA supplementation. Collectively, our data shed light on the novel mechanism: matrix stiffness-suppressed FADS1 drives AA-replied ferroptosis inhibition, ultimately promoting PDAC stemness. Targeting the FADS1-AA-ferroptosis axis may provide practicable opportunities for the therapy of PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.